Patients with hematological malignancies have a risk of developing graft-versus-host disease (GVHD) following allogeneic hematopoietic stem-cell transplantation. The addition of ATG to prophylaxis regimens decreases the incidence of GVHD without compromising overall survival in these patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Finke, J. et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 10, 855–864 (2009).
Mohty, M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21, 1387–1394 (2007).
Cornelissen, J. J. et al. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp. Hematol. 31, 855–864 (2003).
Cutler, C. & Antin, J. H. Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells 19, 108–117 (2001).
Bacigalupo, A. et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98, 2942–2947 (2001).
Wagner, J. E., Thompson, J. S., Carter, S. L. & Kernan, N. A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trial. Lancet 366, 733–741 (2005).
Gross, T. G. et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant. 23, 251–258 (1999).
van Esser, J. W. et al. Prevention of Epstein–Barr virus—lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99, 4364–4369 (2002).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Brunstein, C. ATG and Newton's third law of motion. Nat Rev Clin Oncol 7, 9–10 (2010). https://doi.org/10.1038/nrclinonc.2009.192
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.192
